O	0	3	Fas	Fas	NN	B-NP
O	3	4	-	-	HYPH	I-NP
O	4	13	signaling	signaling	NN	I-NP
O	14	17	and	and	CC	I-NP
O	18	25	effects	effect	NNS	I-NP
O	26	28	on	on	IN	B-PP
O	29	37	receptor	receptor	NN	B-NP
O	38	46	tyrosine	tyrosine	NN	I-NP
O	47	53	kinase	kinase	NN	I-NP
O	54	60	signal	signal	NN	I-NP
O	61	73	transduction	transduction	NN	I-NP
O	74	76	in	in	IN	B-PP
O	77	82	human	human	JJ	B-NP
B-Cell	83	89	breast	breast	NN	I-NP
I-Cell	90	100	epithelial	epithelial	JJ	I-NP
I-Cell	101	106	cells	cell	NNS	I-NP
O	106	107	.	.	.	O

O	109	112	Fas	Fas	NN	B-NP
O	112	113	-	-	HYPH	B-PP
O	113	121	mediated	mediate	VBN	B-NP
B-Cell	122	126	cell	cell	NN	I-NP
O	127	132	death	death	NN	I-NP
O	133	136	was	be	VBD	B-VP
O	137	145	examined	examine	VBN	I-VP
O	146	148	in	in	IN	B-PP
B-Cell	149	152	MCF	MCF	NN	B-NP
I-Cell	152	153	-	-	HYPH	B-NP
I-Cell	153	157	10AT	10AT	NN	I-NP
I-Cell	158	171	preneoplastic	preneoplastic	JJ	I-NP
I-Cell	172	177	human	human	JJ	I-NP
I-Cell	178	184	breast	breast	NN	I-NP
I-Cell	185	195	epithelial	epithelial	JJ	I-NP
I-Cell	196	201	cells	cell	NNS	I-NP
O	201	202	.	.	.	O

O	203	212	Treatment	Treatment	NN	B-NP
O	213	217	with	with	IN	B-PP
O	218	222	anti	anti	AFX	B-NP
O	222	223	-	-	HYPH	I-NP
O	223	226	Fas	Fas	NN	I-NP
O	227	230	for	for	IN	B-PP
O	231	233	48	48	CD	B-NP
O	234	235	h	h	NN	I-NP
O	236	243	induced	induce	VBD	B-VP
O	244	253	apoptosis	apoptosis	NN	B-NP
O	254	258	with	with	IN	B-PP
B-Cell	259	264	cells	cell	NNS	B-NP
O	265	275	exhibiting	exhibit	VBG	B-VP
O	276	283	typical	typical	JJ	B-NP
O	284	293	apoptotic	apoptotic	JJ	I-NP
O	294	302	features	feature	NNS	I-NP
O	303	312	including	include	VBG	B-PP
O	313	317	loss	loss	NN	B-NP
O	318	320	of	of	IN	B-PP
B-Cell	321	325	cell	cell	NN	B-NP
O	326	333	contact	contact	NN	I-NP
O	333	334	,	,	,	O
O	335	347	condensation	condensation	NN	B-NP
O	348	350	of	of	IN	B-PP
B-Cellular_component	351	360	chromatin	chromatin	NN	B-NP
O	360	361	,	,	,	O
O	362	365	and	and	CC	O
O	366	375	increased	increase	VBN	B-NP
O	376	384	staining	staining	NN	I-NP
O	385	387	of	of	IN	B-PP
O	388	391	the	the	DT	B-NP
B-Cellular_component	392	399	nuclear	nuclear	JJ	I-NP
I-Cellular_component	400	408	membrane	membrane	NN	I-NP
O	408	409	.	.	.	O

O	410	413	DNA	DNA	NN	B-NP
O	414	427	fragmentation	fragmentation	NN	I-NP
O	428	436	occurred	occur	VBD	B-VP
O	437	439	in	in	IN	B-PP
O	440	448	response	response	NN	B-NP
O	449	451	to	to	TO	B-PP
O	452	456	anti	anti	AFX	B-NP
O	456	457	-	-	HYPH	I-NP
O	457	460	Fas	Fas	NN	I-NP
O	461	470	treatment	treatment	NN	I-NP
O	470	471	.	.	.	O

O	472	476	Anti	Anti	AFX	B-NP
O	476	477	-	-	HYPH	I-NP
O	477	480	Fas	Fas	NN	I-NP
O	481	490	treatment	treatment	NN	I-NP
O	491	499	resulted	result	VBD	B-VP
O	500	502	in	in	IN	B-PP
O	503	512	decreased	decrease	VBN	B-NP
O	513	516	p53	p53	NN	I-NP
O	517	524	protein	protein	NN	I-NP
O	525	531	levels	level	NNS	I-NP
O	531	532	,	,	,	O
O	533	538	while	while	IN	B-SBAR
O	539	542	bcl	bcl	NN	B-NP
O	542	543	-	-	HYPH	B-NP
O	543	544	2	2	CD	I-NP
O	545	548	and	and	CC	O
O	549	552	bax	bax	NN	B-NP
O	553	560	protein	protein	NN	I-NP
O	561	567	levels	level	NNS	I-NP
O	568	576	remained	remain	VBD	B-VP
O	577	587	unaffected	unaffected	JJ	B-ADJP
O	587	588	.	.	.	O

B-Cell	589	594	Cells	Cell	NNS	B-NP
O	595	602	treated	treat	VBN	B-VP
O	603	607	with	with	IN	B-PP
O	608	612	anti	anti	AFX	B-NP
O	612	613	-	-	HYPH	I-NP
O	613	616	Fas	Fas	NN	I-NP
O	617	621	also	also	RB	B-ADVP
O	622	631	exhibited	exhibit	VBD	B-VP
O	632	641	increased	increase	VBN	B-NP
O	642	650	tyrosine	tyrosine	NN	I-NP
O	651	666	phosphorylation	phosphorylation	NN	I-NP
O	667	669	of	of	IN	B-PP
O	670	673	the	the	DT	B-NP
O	674	675	c	c	NN	I-NP
O	675	676	-	-	HYPH	B-VP
O	676	679	met	meet	VBN	B-NP
O	680	686	growth	growth	NN	I-NP
O	687	693	factor	factor	NN	I-NP
O	694	702	receptor	receptor	NN	I-NP
O	703	711	tyrosine	tyrosine	NN	I-NP
O	712	718	kinase	kinase	NN	I-NP
O	718	719	.	.	.	O

O	720	739	Immunoprecipitation	Immunoprecipitation	NN	B-NP
O	740	751	experiments	experiment	NNS	I-NP
O	752	764	demonstrated	demonstrate	VBD	B-VP
O	765	769	that	that	IN	B-SBAR
O	770	773	Fas	Fas	NN	B-NP
O	774	784	associated	associate	VBN	B-VP
O	785	789	with	with	IN	B-PP
O	790	791	c	c	NN	B-NP
O	791	792	-	-	HYPH	I-NP
O	792	797	erbB2	erbB2	NN	I-NP
O	798	801	and	and	CC	I-NP
O	802	803	c	c	NN	I-NP
O	803	804	-	-	HYPH	B-NP
O	804	807	met	meet	VBN	B-VP
O	808	810	in	in	IN	B-PP
O	811	820	untreated	untreated	JJ	B-NP
B-Cell	821	826	cells	cell	NNS	I-NP
O	826	827	.	.	.	O

O	828	837	Treatment	Treatment	NN	B-NP
O	838	842	with	with	IN	B-PP
O	843	847	anti	anti	AFX	B-NP
O	847	848	-	-	HYPH	I-NP
O	848	851	Fas	Fas	NN	I-NP
O	851	852	,	,	,	O
O	853	860	however	however	RB	B-ADVP
O	860	861	,	,	,	O
O	862	875	significantly	significantly	RB	B-ADVP
O	876	885	decreased	decrease	VBD	B-VP
O	886	889	Fas	Fas	NN	B-NP
O	889	890	-	-	HYPH	B-NP
O	890	891	c	c	NN	I-NP
O	891	892	-	-	HYPH	I-NP
O	892	897	erbB2	erbB2	NN	I-NP
O	898	901	and	and	CC	I-NP
O	902	905	Fas	Fas	NN	I-NP
O	905	906	-	-	HYPH	B-NP
O	906	907	c	c	NN	I-NP
O	907	908	-	-	HYPH	O
O	908	911	met	meet	VBN	B-NP
O	912	923	association	association	NN	I-NP
O	923	924	.	.	.	O

O	925	929	Anti	Anti	AFX	B-NP
O	929	930	-	-	HYPH	I-NP
O	930	933	Fas	Fas	NN	I-NP
O	934	943	treatment	treatment	NN	I-NP
O	944	946	of	of	IN	B-PP
O	947	952	these	these	DT	B-NP
B-Cell	953	958	cells	cell	NNS	I-NP
O	959	965	caused	cause	VBD	B-VP
O	966	967	a	a	DT	B-NP
O	968	979	significant	significant	JJ	I-NP
O	980	988	decrease	decrease	NN	I-NP
O	989	991	in	in	IN	B-PP
O	992	996	p120	p120	NN	B-NP
O	996	997	-	-	HYPH	B-NP
O	997	1000	GAP	GAP	NN	I-NP
O	1001	1007	levels	level	NNS	I-NP
O	1007	1008	,	,	,	O
O	1009	1012	ERK	ERK	NN	B-NP
O	1012	1013	-	-	HYPH	B-NP
O	1013	1014	1	1	CD	I-NP
O	1015	1021	levels	level	NNS	I-NP
O	1021	1022	,	,	,	O
O	1023	1026	and	and	CC	O
O	1027	1042	phosphorylation	phosphorylation	NN	B-NP
O	1042	1043	,	,	,	O
O	1044	1046	as	as	RB	B-CONJP
O	1047	1051	well	well	RB	I-CONJP
O	1052	1054	as	as	IN	I-CONJP
O	1055	1059	Grb2	Grb2	NN	B-NP
O	1059	1060	-	-	HYPH	I-NP
O	1060	1064	Sosl	Sosl	NN	I-NP
O	1065	1068	and	and	CC	I-NP
O	1069	1072	MEK	MEK	NN	I-NP
O	1072	1073	-	-	HYPH	B-NP
O	1073	1074	1	1	CD	I-NP
O	1074	1075	-	-	HYPH	I-NP
O	1075	1078	ERK	ERK	NN	I-NP
O	1078	1079	-	-	HYPH	B-NP
O	1079	1080	1	1	CD	I-NP
O	1081	1092	association	association	NN	I-NP
O	1092	1093	.	.	.	O

O	1094	1099	These	These	DT	B-NP
O	1100	1107	results	result	NNS	I-NP
O	1108	1112	show	show	VBP	B-VP
O	1113	1117	that	that	IN	B-SBAR
O	1118	1121	Fas	Fas	NN	B-NP
O	1121	1122	-	-	HYPH	B-NP
O	1122	1131	signaling	signaling	NN	I-NP
O	1132	1139	exerted	exert	VBD	B-VP
O	1140	1141	a	a	DT	B-NP
O	1142	1153	suppressive	suppressive	JJ	I-NP
O	1154	1160	effect	effect	NN	I-NP
O	1161	1163	on	on	IN	B-PP
O	1164	1167	p53	p53	NN	B-NP
O	1168	1174	levels	level	NNS	I-NP
O	1175	1178	and	and	CC	B-PP
O	1179	1181	on	on	IN	B-PP
O	1182	1192	downstream	downstream	JJ	B-NP
O	1193	1202	effectors	effector	NNS	I-NP
O	1203	1205	of	of	IN	B-PP
O	1206	1214	receptor	receptor	NN	B-NP
O	1215	1223	tyrosine	tyrosine	NN	I-NP
O	1224	1230	kinase	kinase	NN	I-NP
O	1231	1237	signal	signal	NN	I-NP
O	1238	1250	transduction	transduction	NN	I-NP
O	1250	1251	,	,	,	O
O	1252	1259	thereby	thereby	RB	B-VP
O	1260	1268	ensuring	ensure	VBG	I-VP
B-Cell	1269	1273	cell	cell	NN	B-NP
O	1274	1279	death	death	NN	I-NP
O	1279	1280	.	.	.	O

